These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26673009)

  • 1. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
    Xu Y; Dong B; Huang J; Kong W; Xue W; Zhu Y; Zhang J; Huang Y
    Oncotarget; 2016 Jan; 7(3):3233-44. PubMed ID: 26673009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
    Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.
    Jain M; Zhang L; He M; Zhang YQ; Shen M; Kebebew E
    Endocr Relat Cancer; 2013 Jun; 20(3):361-70. PubMed ID: 23533247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.
    Li W; Li J; Wang Y; Zhang K; Li N; Tian Z; Ni B; Wang H; Ruan Z
    Oncotarget; 2016 Dec; 7(49):80586-80598. PubMed ID: 27811359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
    Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
    Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
    J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
    Gagliano T; Gentilin E; Benfini K; Di Pasquale C; Tassinari M; Falletta S; Feo C; Tagliati F; Uberti ED; Zatelli MC
    Endocrine; 2014 Dec; 47(3):943-51. PubMed ID: 25096913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer.
    Demeure MJ; Stephan E; Sinari S; Mount D; Gately S; Gonzales P; Hostetter G; Komorowski R; Kiefer J; Grant CS; Han H; Von Hoff DD; Bussey KJ
    Ann Surg; 2012 Jan; 255(1):140-6. PubMed ID: 22156929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis.
    Ren L; Yang Y; Li W; Zheng X; Liu J; Li S; Yang H; Zhang Y; Ge B; Zhang S; Fu W; Dong D; Du G; Wang J
    J Transl Med; 2022 Oct; 20(1):444. PubMed ID: 36184616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
    Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
    Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma.
    Germano A; Rapa I; Duregon E; Votta A; Giorcelli J; Buttigliero C; Scagliotti GV; Volante M; Terzolo M; Papotti M
    Endocr Pathol; 2017 Jun; 28(2):95-102. PubMed ID: 28271381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
    Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
    Doghman M; Lalli E
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma.
    Ronchi CL; Sbiera S; Volante M; Steinhauer S; Scott-Wild V; Altieri B; Kroiss M; Bala M; Papotti M; Deutschbein T; Terzolo M; Fassnacht M; Allolio B
    PLoS One; 2014; 9(8):e105855. PubMed ID: 25144458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
    Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
    Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
    Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
    Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
    Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
    Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.
    Kroiss M; Sbiera S; Kendl S; Kurlbaum M; Fassnacht M
    Horm Cancer; 2016 Dec; 7(5-6):345-355. PubMed ID: 27631436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics.
    Zhang J; Wu L; Su T; Liu H; Jiang L; Jiang Y; Wu Z; Chen L; Li H; Zheng J; Sun Y; Peng H; Han R; Ning G; Ye L; Wang W
    Front Endocrinol (Lausanne); 2024; 15():1365321. PubMed ID: 38779454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
    Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
    Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.